Seeking Alpha

Bristol Myers Squibb (BMY) +2.3% premarket after results from an early-stage study show its...

Bristol Myers Squibb (BMY) +2.3% premarket after results from an early-stage study show its BMS-936658 experimental drug that helps the immune system attack cancer cells can reduce the size of tumors in patients with melanoma and non-small cell lung cancers. (also)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|